Sanofi and Lexicon's Zynquista (sotagliflozin) Receive EU's MAA to Treat Type-1 Diabetes in Adults
Shots:
- The authorization is based on inTandem study consisting of three P-III trials assessing sotagliflozin (200/400 mg) vs insulin as monothx in 3000 adults with inadequately controlled T1D
- The study resulted reduction in average blood sugar (HbA1c)- body weight- systolic blood pressure- improvement of time in target blood sugar range- patient-reported outcomes within 24 weeks
- Zynquista (sotagliflozin-PO) is an inhibitor of SGLT1 and SGLT2 proteins and is being evaluated in a program of 11 trials for T2D in adults. In Nov-2015 Lexicon and Sanofi collaborated to develop and commercialize sotagliflozin to treat diabetes
Ref: Sanofi| Image: Investors
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com